Today Zimmer Biomet Holdings Inc Had High Bullish Options Activity

 Today Zimmer Biomet Holdings Inc Had High Bullish Options Activity

In today’s session Zimmer Biomet Holdings Inc (ZBH) registered an unusually high (1,038) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the December, 2016 call, expecting serious ZBH increase. With 1,038 contracts traded and 13574 open interest for the Dec, 16 contract, it seems this is a quite bullish bet. The option with symbol: ZBH161216C00135000 closed last at: $0.75 or 66.7% up. About 2.20M shares traded hands or 59.42% up from the average. Zimmer Biomet Holdings Inc (NYSE:ZBH) has declined 1.22% since March 30, 2016 and is downtrending. It has underperformed by 4.23% the S&P500.

Analysts await Zimmer Biomet Holdings Inc (NYSE:ZBH) to report earnings on November, 3. They expect $1.79 EPS, up 9.15% or $0.15 from last year’s $1.64 per share. ZBH’s profit will be $307.98M for 14.64 P/E if the $1.79 EPS becomes a reality. After $2.02 actual EPS reported by Zimmer Biomet Holdings Inc for the previous quarter, Wall Street now forecasts -11.39% negative EPS growth.

Zimmer Biomet Holdings Inc (NYSE:ZBH) Ratings Coverage

Out of 15 analysts covering Zimmer Biomet Holdings (NYSE:ZBH), 12 rate it a “Buy”, 1 “Sell”, while 2 “Hold”. This means 80% are positive. Zimmer Biomet Holdings has been the topic of 22 analyst reports since August 27, 2015 according to StockzIntelligence Inc. Canaccord Genuity maintained it with “Buy” rating and $150 target price in Friday, September 4 report. The rating was initiated by UBS on Tuesday, September 22 with “Neutral”. The rating was maintained by Needham with “Buy” on Friday, July 29. SunTrust initiated Zimmer Biomet Holdings Inc (NYSE:ZBH) on Thursday, August 11 with “Buy” rating. The rating was initiated by Suntrust Robinson on Thursday, August 11 with “Buy”. The rating was initiated by Guggenheim with “Neutral” on Thursday, June 9. The firm has “Overweight” rating given on Tuesday, August 23 by Barclays Capital. The stock of Zimmer Biomet Holdings Inc (NYSE:ZBH) earned “Sell” rating by Citigroup on Thursday, November 12. The firm has “Buy” rating given on Wednesday, May 25 by Argus Research. Zacks downgraded the shares of ZBH in a report on Friday, August 28 to “Buy” rating.

According to Zacks Investment Research, “Zimmer Biomet Holdings, Inc. is a musculoskeletal healthcare company. The company design, manufacture and market orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants; and related surgical products. Zimmer Biomet Holdings, Inc., formerly known as Zimmer Holdings, Inc., is based in Warsaw, United States.”

Zimmer Biomet Holdings, Inc., formerly Zimmer Holdings, Inc., is engaged designing, manufacturing and marketing orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants, and related surgical products. The company has a market cap of $18.04 billion. The Company’s products and solutions helps treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It has a 94.28 P/E ratio. The Firm manages its activities through three geographic operating divisions: the Americas, consists of the United States and includes other North, Central and South American markets; EMEA, consists of Europe and includes the Middle East and African markets, and Asia Pacific, consists of Japan and includes other Asian and Pacific markets.

ZBH Company Profile

Zimmer Biomet Holdings, Inc., formerly Zimmer Holdings, Inc., incorporated on January 12, 2001, is engaged in designing, manufacturing and marketing orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma (S.E.T.) products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants, and related surgical products. The Company’s products and solutions helps treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. The Firm manages its activities through three geographic operating divisions: the Americas, comprising principally of the United States and includes other North, Central and South American markets; EMEA, comprising of principally of Europe and includes the Middle East and African markets, and Asia Pacific, comprising primarily of Japan and includes other Asian and Pacific markets. The Company’s four product category divisions include Americas Spine, Bone Healing Craniomaxillofacial and Thoracic (CMF) and Dental.

More recent Zimmer Biomet Holdings Inc (NYSE:ZBH) news were published by: Wsj.com which released: “Zimmer Biomet Cuts Forecasts” on October 31, 2016. Also Businesswire.com published the news titled: “Glancy Prongay & Murray LLP Commences Investigation on Behalf of Zimmer Biomet …” on November 01, 2016. Prnewswire.com‘s news article titled: “Zimmer Biomet Acquires RespondWell® Telerehabilitation Platform for Zimmer …” with publication date: October 27, 2016 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment